A retrospective US analysis found AI-ECG and AI-Echo identified probable ATTR-CM in adults aged 50–95, with dual-positive screens associated with higher mortality.
A retrospective study of 164 patients receiving disease-modifying therapy for ATTR-CM found genetic testing declined with age; 27.3% of tested patients had pathogenic TTR variants.
An LLM chart-review study of 24,080 adults identified 218 untreated patients with suspected ATTR-CA and incomplete evaluations, most lacking a PYP order.
A retrospective US analysis found AI-ECG and AI-Echo identified probable ATTR-CM in adults aged 50–95, with dual-positive screens associated with higher mortality.
A retrospective study of 164 patients receiving disease-modifying therapy for ATTR-CM found genetic testing declined with age; 27.3% of tested patients had pathogenic TTR variants.
An LLM chart-review study of 24,080 adults identified 218 untreated patients with suspected ATTR-CA and incomplete evaluations, most lacking a PYP order.
A probe-based immunoassay yielded an AUC of 0.819 for distinguishing ATTR-CM from cardiovascular controls, with lower TTR stability also observed in mildly symptomatic patients.